Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa - Wikidata - awgldk - TriplyDB

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa

http://www.wikidata.org/entity/Q36897863

about

Antiretroviral therapy response among HIV-2 infected patients: a systematic review Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program.The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration Genotypic resistance profiles of HIV-2-treated patients in West Africa.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.Update on human immunodeficiency virus (HIV)-2 infection.In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.Clinical management of HIV drug resistance.An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.Antiretroviral drug resistance in human immunodeficiency virus type 2.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.A Comparison of the Natural History of HPV Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa.Novel inhibitors of human immunodeficiency virus type 2 infectivity.Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1 Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.

P2860

Q27003854-7558BFEC-BD4E-4358-A528-C8692AC15911 Q28538242-A5E25A2B-5CC6-432E-9EB0-CE0D533462B4 Q33670735-9CFB1243-04B1-4517-A4CA-203891154592 Q33681279-19D9F8AB-E429-49B5-981E-EEEBAAB808E5 Q33891896-7FB38183-CF5B-42A7-A163-ED2BB22F6BD6 Q33954546-67D8A0D9-1B25-4BDD-B9F2-6BDB431635F0 Q33963958-4E8BE2DC-2EAA-4A3E-818E-B62B4A26CA32 Q34428902-0166B1E1-825C-4B1E-9C08-F63F26DCE228 Q34730950-5A34D33E-332C-48DC-BC63-50822E0495D9 Q34742090-6A5475A5-F36A-4FA2-89CF-59E3A6F68C02 Q34992731-A48C0F25-186C-4E3A-A1FA-DD5748080DCE Q35008562-63B49C2A-7D9F-4691-A915-3B0E32564FA4 Q35019924-2877AE80-1CDD-4883-85B2-68EC28D0E143 Q35083423-AD5059D0-0867-461D-B569-20E300C08C4A Q35260403-05AA050B-CCC8-47FB-891B-7CD98060290F Q35261045-189B7A17-CC82-42EF-9E0E-06FCB7226BAC Q35273824-2ECDECDD-01C9-406F-946B-866FFF4D06F9 Q35674666-5D9F324E-DF82-4A4E-8362-C163EAF87271 Q35943486-8E39C4BD-7B9F-4D4A-921D-7428ADFA30ED Q36077418-482ADBB5-A9C4-438A-B5EC-799DDE3AA549 Q36239297-28B7D542-1D02-46AA-8299-67D9BE4366E3 Q36290647-D12F145F-F250-4BEE-B722-521B27C298BD Q36564668-2FD88FA1-F123-485E-9CC2-DBC64EB87440 Q36839676-FF667519-E4E8-4DC7-9C28-582B4F15DF86 Q37026564-5C265287-ABCF-4D90-B67B-5E0AB53A9D31 Q37496287-15ED0AF5-3987-41B0-B3AA-9B945236496D Q37859395-17CBDA2F-051F-43C2-A552-3AC9601510EC Q37967232-FA81DB0D-25EE-44A3-A63B-42139895BA7B Q38755690-8B962DFF-F7C4-40B8-BA01-DA5A0CC01C7C Q38780225-2CF94316-BB11-4334-947A-ED5EFEAB5419 Q38967949-880FAC50-2B7F-44F3-B527-D9773721123A Q40278530-668FEEA2-A006-414B-976A-8B0977D2DEF7 Q40413304-7B799A05-20DC-48FF-8BB1-91218E0F2987 Q41766628-D02BC1C2-451E-41BF-83D5-34C202981CE6 Q44990505-6045F5CC-76A4-4E3D-A589-F4CFAB1D5B6A Q46590840-4D2BB240-D3EF-49DF-AA91-987F089069C8 Q47560712-8DA8178F-B5A1-4E3A-A84A-887D9BABBAB2

P2860

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa

http://www.wikidata.org/entity/Q36897863

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Emergence of multiclass drug-r ...... in resouce-limited West Africa

@en

type

label

Emergence of multiclass drug-r ...... in resouce-limited West Africa

@en

prefLabel

Emergence of multiclass drug-r ...... in resouce-limited West Africa

@en

P1433

Q36897863-14E3E7CE-4A0E-4341-9A0A-642B01AD1184

P1476

Q36897863-F76E9B60-E022-444E-AA56-5218A17A1C6A

P2093

Q36897863-11A6D8DF-5892-4E71-89A2-7239B0D96280

Q36897863-38A617B8-FE5C-4EBB-A271-FE329A443CDC

Q36897863-4B5A99A6-EEF0-4C79-93FC-AFA737B6C353

Q36897863-51A17733-CEEF-459D-9BDC-B395D0ACF8B8

Q36897863-52235492-71E4-4EB9-91BA-E1245BBBD9E5

Q36897863-56619894-8B0E-4F09-9D6B-2732F47AEC62

Q36897863-56796DC5-91D7-4957-B903-33B837D4AF7D

Q36897863-5A0A5241-2BBC-4245-8F43-4FE7772F0623

Q36897863-86B58F8C-B18A-4C5A-B688-AEA79E3F34DA

Q36897863-87B45C3E-07C6-4CBD-85D7-BEA8141968A2

P2860

Q36897863-026E4945-EAF4-4C69-94C6-CC75F9B097ED

Q36897863-0FA581A7-327F-416E-BC19-38F77962FF43

Q36897863-227448DB-0225-45EE-9305-7487A05BCCA3

Q36897863-2FEDDAE4-7C5B-4946-A68F-ECF8BAB26D6A

Q36897863-301021FB-E1FB-48FE-9824-187FF9985B3C

Q36897863-3281E1ED-561E-467A-A048-5DF7DCA64491

Q36897863-3290FECA-64C5-457F-B7E2-B34F30A016D6

Q36897863-33787938-4102-4D6D-87E1-7786B6A13AAD

Q36897863-383C5578-E33A-486F-9B07-C7E4560E2CC3

Q36897863-39331BCA-4101-4B95-A082-51202BF9AE24

P304

Q36897863-1D51B6C9-047C-4EA6-9866-0801608B1FB2

P31

Q36897863-4B604F1A-560B-4625-8399-2ECF42966028

P356

Q36897863-AC6C11C9-13FC-461C-844B-209A25F9F320

P407

Q36897863-B6F59250-C775-46DB-9FF0-AB15FAFBA18F

P433

Q36897863-ABC28E86-B7E4-4033-903B-028187BE002B

P478

Q36897863-DA054E46-546B-4ED1-8A44-7C378D3B977F

P50

Q36897863-1FAB4204-AAE4-426C-B014-F53A9BAEBA7B

Q36897863-E74B199B-2D3C-4A04-9C42-FDC93B6E8579

P577

Q36897863-D327F8AA-0BF8-4FDF-AB25-10AD4F3FF281

P5875

Q36897863-1BB532BD-C225-49ED-9ABD-6ADD30EBD7C4

P698

Q36897863-5D42E2E4-47E4-41D8-9D3C-F413C971F82B

P921

Q36897863-85F53704-CE90-440D-B4CF-A00E4F5E2729

Q36897863-AA0B2B0B-FBF8-4E1C-B18B-4D73EF1FAD7E

Q36897863-FBD9EC99-DD0B-4420-95A1-57D01C248555

P932

Q36897863-AD5334CC-A944-4FD2-9460-935A1816A3D6

P356

P1433

Clinical Infectious Diseases

P1476

Emergence of multiclass drug-r ...... in resouce-limited West Africa

@en

P2093

Alison K Starling

http://www.w3.org/2001/XMLSchema#string

Cheikh T Ndour

http://www.w3.org/2001/XMLSchema#string

Fatima Sall

http://www.w3.org/2001/XMLSchema#string

Fatou Traore

http://www.w3.org/2001/XMLSchema#string

James I Mullins

http://www.w3.org/2001/XMLSchema#string

Kim G Wong

http://www.w3.org/2001/XMLSchema#string

Louise Fortes

http://www.w3.org/2001/XMLSchema#string

Macoumba Toure

http://www.w3.org/2001/XMLSchema#string

Nancy B Kiviat

http://www.w3.org/2001/XMLSchema#string

Ndeye Mery Dia Badiane

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

Slower heterosexual spread of HIV-2 than HIV-1.

Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database

Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

P304

476-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/596504

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey S. Gottlieb

Donovan J Anderson

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23787688

http://www.w3.org/2001/XMLSchema#string

P698

19143530

http://www.w3.org/2001/XMLSchema#string

P921

Afelika ya Lumonso

antiretroviral drug

P932

3671065

http://www.w3.org/2001/XMLSchema#string